AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22321131
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the normal drug education provided in their schools
Trial: 17464140
Drug: Slow extended
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow extended daily dialysis (SLEDD)
Trial: 12200949
Drug: Clonidine 75
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 75 micrograms with prilocaine 75 mg
Trial: 12200949
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prilocaine 75 mg alone)
Trial: 3397523
Drug: Lofepramine 70
RxNorm normalized name: lofepramine 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofepramine 70 mg
Trial: 3397523
Drug: Lofepramine 140
RxNorm normalized name: lofepramine
DrugBank: Lofepramine (DB13411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofepramine 140 mg
Trial: 29462482
Drug: Adjuvant S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant S-1 therapy
Trial: 28169983
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (preoperative education and postoperative routine physical therapy)
Trial: 26314389
Drug: Budesonide (swallowed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (swallowed topical corticosteroids)
Trial: 23127920
Drug: CIDR-G of
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIDR-G of first use (new devices)
Trial: 23127920
Drug: CIDR-G of
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIDR-G of third use (previously used twice)
Trial: 23127920
Drug: CIDR-G of
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIDR-G of second use (previously used once)
Trial: 12697590
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 2 ng ml(‐1) (low)
Trial: 12697590
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 4 ng ml(‐1) (medium)
Trial: 12697590
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 8 ng ml(‐1) (high)
Trial: 2931421
Drug: Procaterol inhaled
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol inhaled (10 micrograms)
Trial: 2931421
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered with a pressurized metered-dose inhaler)
Trial: 29450636
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (CYC) 6 × 500 mg fortnightly
Trial: 29450636
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CYC) 6 × 750 mg/m2 four-weekly
Trial: 29450636
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CYC)
Trial: 29450636
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (CYC)
Trial: 26826547
Drug: HantavaxTM (three-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HantavaxTM (three-dose schedule at 0, 1, and 13 months)
Trial: 22283848
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate (4 g day⁻¹ for 15 days)
Trial: 22283848
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg single dose preceded by 15 days of placebo)
Trial: 19575740
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 3350 (PEG), 3.45 g t.i.d. orally for 30 days
Trial: 10361110
Drug: Extended ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended ATRA (5-day course before chemotherapy)
Trial: 10361110
Drug: Extended ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended ATRA in patients with WBC < 10 x 10(9)/L
Trial: 10361110
Drug: RT-PCR monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT-PCR monitoring after third chemotherapy course
Trial: 28705210
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical stimulation of the foot for 60 minutes daily for 3 days after surgery
Trial: 16986228
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg plus HCTZ 25 mg once daily
Trial: 30772975
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose group (300 mg clopidogrel)
Trial: 30772975
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose group (75 mg clopidogrel)
Trial: 30772975
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose group (CYP2C19*2 carriers)
Trial: 30772975
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose group (CYP2C19*2 carriers)
Trial: 29995359
Drug: Tianeptine 25-50
RxNorm normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine 25-50 mg/d
Trial: 26893309
Drug: Soft tissue
RxNorm normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft tissue treatment (Astym) and eccentric exercise
Trial: 19875236
Drug: Subcutaneous pedicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous pedicle island flap
Trial: 15750362
Drug: Qigong lessons
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qigong lessons for 20 minutes at least twice weekly over a period of 6 months
Trial: 12150309
Drug: Fixed-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose warfarin
Trial: 10215274
Drug: Prior aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior aspirin use
Trial: 8530644
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone agonist (GnRHa, triptorelin) 0.1 mg s.c. injection
Trial: 8530644
Drug: Human chorionic
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotrophin (HCG) 10,000 IU i.m. injection
Trial: 320109
Drug: D-penicillamine (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (1-2 g daily)
Trial: 320109
Drug: Prednisone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (15 mg daily)
Trial: 26669544
Drug: External Connection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Connection (EC) implants
Trial: 26669544
Drug: Internal Connection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal Connection (IC) implants
Trial: 23115085
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rifampicin (600 mg)
Trial: 23115085
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of rifampicin (600 mg)
Trial: 18258749
Drug: Licabazepine 500
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licabazepine 500 mg single dose
Trial: 18258749
Drug: Licabazepine 500
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licabazepine 500 mg multiple doses (500 mg bid on days 3 to 6)
Trial: 18258749
Drug: Licabazepine 500
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licabazepine 500 mg single dose under fasted conditions
Trial: 18258749
Drug: Licabazepine 500
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licabazepine 500 mg single dose under fed conditions
Trial: 16239861
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (GCBT) for 12 weeks
Trial: 12407614
Drug: Oral amiodarone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone, 15 mg/kg, 4 hours after arrival in the intensive care unit, followed by 7 mg/kg/d until hospital discharge
Trial: 12407614
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone and Placebo
Trial: 9924052
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch for 5 months with nicotine nasal spray for 1 year
Trial: 9924052
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch with placebo spray
Trial: 7226565
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg intravenous)
Trial: 23764566
Drug: MMT +
RxNorm normalized name: RESERVOIR,EXTENDED #MMT-342
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMT + AA (methadone maintenance treatment plus auricular acupuncture)
Trial: 23764566
Drug: MMT (methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMT (methadone maintenance treatment)
Trial: 21811051
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg α‐lipoic acid (ALA) per day
Trial: 16926119
Drug: mini‐BCP supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mini‐BCP supplemented with potassium (initial/others: 15.4/9.8 mEq/L) and magnesium (initial/others: 6.5/4.0 mEq/L)
Trial: 16926119
Drug: 4:1‐diluted BCP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4:1‐diluted BCP modified with Buckberg solution
Trial: 7598243
Drug: perphenazine 5
RxNorm normalized name: perphenazine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perphenazine 5 mg
Trial: 1964885
Drug: NET-OEN (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NET-OEN (50 mg) + E2 valerate (5 mg) given every month
Trial: 1964885
Drug: NET-OEN (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NET-OEN (200 mg) given every 2 months
Trial: 155389
Drug: Tryptophan-nicotinamide-imipramine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan-nicotinamide-imipramine combination
Trial: 26473975
Drug: Regular intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intake of carotenoids from supplements and medications in amounts > 6.8 mg/d (upper tertile)
Trial: 23647889
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention for 1 hour daily for 3 months along with oral hypoglycemic drugs
Trial: 23647889
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic drugs
Trial: 18534438
Drug: Enoxaparin 30
RxNorm normalized name: ENOXAPARIN 30MG/0.3ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg SC BID
Trial: 16887327
Drug: Drospirenone containing
RxNorm normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drospirenone containing oral contraceptive pill (Yasmin)
Trial: 15083986
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (beclomethasone metered-dose inhaler, tapering 4-week course)
Trial: 9496526
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg intravenously
Trial: 2647270
Drug: desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: desipramine (150 mg/day)
Trial: 30159779
Drug: DC vaccine
RxNorm normalized name: Recombinant chimeric COVID-19 DC vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC vaccine (DCV)
Trial: 25408735
Drug: Clarithromycin (2×500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (2×500 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 14 days
Trial: 25408735
Drug: Azithromycin (1×250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1×250 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 10 days
Trial: 17698978
Drug: Individualized herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized herbal treatment from qualified herbal practitioners (n = 15), six consultations over 5 months
Trial: 17698978
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 30) offered treatment after waiting 4 months
Trial: 17698978
Drug: Individualized herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized herbal treatment
Trial: 9932956
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon beta-1b (8.0 mIU)
Trial: 9932956
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose interferon beta-1b (1.6 mIU)
Trial: 7586436
Drug: Preoperative steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative steroid (Solumedrol 250 mg IV, n = 16)
Trial: 7586436
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid (n = 9, control group)
Trial: 2310577
Drug: Caudal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal analgesia with bupivacaine (three different dosage regimens)
Trial: 31540980
Drug: Lifastuzumab vedotin
RxNorm normalized name: Lifastuzumab vedotin
DrugBank: Lifastuzumab vedotin (DB15400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifastuzumab vedotin (LIFA) at 2.4 mg/kg once every 3 weeks
Trial: 31540980
Drug: Lifastuzumab vedotin
RxNorm normalized name: Lifastuzumab vedotin
DrugBank: Lifastuzumab vedotin (DB15400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifastuzumab vedotin (LIFA) at doses ≥1.8 mg/kg
Trial: 30722014
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g milk protein concentrate
Trial: 30722014
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g milk protein concentrate
Trial: 30722014
Drug: 45 g
RxNorm normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 g milk protein concentrate
Trial: 22326504
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg atrasentan
Trial: 22326504
Drug: 1.75 mg
RxNorm normalized name: glyburide 1.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.75 mg atrasentan
Trial: 22326504
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg atrasentan (Hispanic subjects)
Trial: 22326504
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg atrasentan (non-Hispanic subjects)
Trial: 22326504
Drug: Maximum doses
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum doses of RAS inhibitors
Trial: 20191466
Drug: Communication about
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Communication about medication costs during visits
Trial: 17412530
Drug: 1MIRP (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 1 month)
Trial: 17412530
Drug: 3MIRP (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 3 months)
Trial: 17412530
Drug: DTC (Delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTC (Delayed Treatment Control)
Trial: 12154111
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (3 ng/kg per minute for 45 minutes) and captopril during low salt balance
Trial: 10834508
Drug: Myeloablative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative therapy followed by allogeneic stem-cell infusion
Trial: 8823101
Drug: Heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuit (Duraflo II), n = 107
Trial: 2994148
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg every morning for 14 days
Trial: 30832742
Drug: IgGAM infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgGAM infusions for 5 days
Trial: 30832742
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment (SoC)
Trial: 30212438
Drug: Integrated smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated smoking cessation intervention (QUIT) - 9-week program with 1 psychoeducation session and 9 weekly 1-hour sessions of cognitive behavioral therapy plus nicotine replacement therapy.
Trial: 30212438
Drug: Enhanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced standard smoking intervention (ETAU) - 9-week program with 1 psychoeducation session and 4 brief weekly check-in sessions plus nicotine replacement therapy.
Trial: 27097348
Drug: 7‐valent pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐valent pneumococcal conjugate vaccine (7vCRM) + DTPa‐IPV‐Hib
Trial: 22417026
Drug: Ketofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketofol (1 mg/kg; 0.5 mg/kg propofol plus 0.5 mg/kg ketamine)
Trial: 10843434
Drug: Inhaled steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroid (budesonide) for 6 weeks
Trial: 10843434
Drug: Inhaled beta2‐agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta2‐agonist (terbutaline) for 6 weeks followed by inhaled steroid for 2 weeks
Trial: 28953631
Drug: TPVBRA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPVBRA with 20 mL 0.25% bupivacaine + 1 μg/kg dexmedetomidine
Trial: 28953631
Drug: TPVBRA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPVBRA with 20 mL 0.25% bupivacaine
Trial: 25955980
Drug: 1.5% Topical
RxNorm normalized name: ZILXI 1.5% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% Topical Diclofenac
Trial: 23369038
Drug: Paracetamol 1,000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1,000 mg sustained release (SR) tablets
Trial: 23369038
Drug: Conventional paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional paracetamol 500 mg tablets
Trial: 21208923
Drug: Heterotypic vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterotypic vaccine
Trial: 19353315
Drug: Biological dressing
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological dressing (Xenoderm)
Trial: 15161118
Drug: Rivastigmine 3-6
RxNorm normalized name: rivastigmine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 3-6 mg/day
Trial: 15161118
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus nimodipine
Trial: 11465702
Drug: Disease-Modifying Antirheumatic
RxNorm normalized name: ANTIRHEUMATICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-Modifying Antirheumatic Drugs (DMARDs)
Trial: 9570492
Drug: Antidepressants treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants treatment for 5 weeks
Trial: 9570492
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to antidepressants
Trial: 8068589
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled infusion of midazolam
Trial: 8068589
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of midazolam
Trial: 3059852
Drug: 0.075 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg.kg‐1 midazolam intravenously 3 to 5 min prior to induction with fentanyl (5 micrograms.kg‐1.min‐1)
Trial: 28276901
Drug: HolisFiit®, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HolisFiit®, a polyphenol-rich food supplement, daily supplementation for 16 weeks